These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23645236)

  • 41. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
    Narula PK; Rehan HS; Unni KE; Gupta N
    Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia.
    Lindenmayer JP; Tedeschi F; Yusim A; Khan A; Kaushik S; Smith RC; Parakadavil M
    Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):185-92. PubMed ID: 22182455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.
    Tybura P; Trześniowska-Drukała B; Bienkowski P; Beszlej A; Frydecka D; Mierzejewski P; Samochowiec A; Grzywacz A; Samochowiec J
    Psychiatry Res; 2014 Oct; 219(2):261-7. PubMed ID: 24930580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone.
    Kaushal J; Bhutani G; Gupta R
    Singapore Med J; 2012 Jul; 53(7):488-92. PubMed ID: 22815019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
    Vázquez-Bourgon J; Ibáñez Alario M; Mayoral-van Son J; Gómez Revuelta M; Ayesa Arriola R; Juncal Ruiz M; Ortiz-García de la Foz V; Crespo Facorro B
    Eur Neuropsychopharmacol; 2020 Oct; 39():46-55. PubMed ID: 32891516
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis.
    Zhang Y; Liu Y; Su Y; You Y; Ma Y; Yang G; Song Y; Liu X; Wang M; Zhang L; Kou C
    BMC Psychiatry; 2017 Nov; 17(1):373. PubMed ID: 29162032
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
    Fleischhacker WW; McQuade RD; Marcus RN; Archibald D; Swanink R; Carson WH
    Biol Psychiatry; 2009 Mar; 65(6):510-7. PubMed ID: 18986646
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
    Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
    Schizophr Res; 2009 May; 110(1-3):80-9. PubMed ID: 19269791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of health services use associated with ziprasidone and olanzapine among schizophrenia and bipolar disorder patients in the USA.
    Jiang Y; Ni W; McGinnis JJ
    Clin Drug Investig; 2014 Jul; 34(7):491-9. PubMed ID: 24858912
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early changes of plasma lipids during treatment with atypical antipsychotics.
    Rettenbacher MA; Ebenbichler C; Hofer A; Kemmler G; Baumgartner S; Edlinger M; Hummer M; Lechleitner M; Fleischhacker WW
    Int Clin Psychopharmacol; 2006 Nov; 21(6):369-72. PubMed ID: 17012984
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
    Volavka J; Czobor P; Derks EM; Bitter I; Libiger J; Kahn RS; Fleischhacker WW;
    J Clin Psychiatry; 2011 Jul; 72(7):955-61. PubMed ID: 21824456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The lipid metabolism abnormality in patients administered with olanzapine].
    Amano T; Hosaka S; Takami H; Sugiyama C; Oda K; Morikawa R
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Nov; 32(5-6):257-61. PubMed ID: 23373312
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
    Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
    Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.
    Weiden PJ; Newcomer JW; Loebel AD; Yang R; Lebovitz HE
    Neuropsychopharmacology; 2008 Apr; 33(5):985-94. PubMed ID: 17637612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
    Weiden PJ; Daniel DG; Simpson G; Romano SJ
    J Clin Psychopharmacol; 2003 Dec; 23(6):595-600. PubMed ID: 14624190
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).
    Strom BL; Eng SM; Faich G; Reynolds RF; D'Agostino RB; Ruskin J; Kane JM
    Am J Psychiatry; 2011 Feb; 168(2):193-201. PubMed ID: 21041245
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
    Jing Y; Kim E; You M; Pikalov A; Tran QV
    J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
    Bobo WV; Bonaccorso S; Jayathilake K; Meltzer HY
    Psychiatry Res; 2011 Sep; 189(2):200-7. PubMed ID: 21802150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.